Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX:NUZ)

Offer Price

A$0.120

per share

Offer Size

A$5,000,000

Open Now!
Apply Now

Neurizon Therapeutics Limited (ASX:NUZ)

NUZ

Lead Manager

Contact - Jake Grbavac

0474 484 982

jake@liquidity.com.au

Offer Price

A$0.120

per share

Offer Size

A$5,000,000

Offer Details

Issue Price (Per Share)

A$0.120

Discount

-9.09%

Offer Size

A$5,000,000

Shares Available

41,666,666

Up to A$5m placement, with the ability to accept overs, of new fully paid ordinary shares.

Board & management participation of approximately A$0.2m

Discount

  • Discount to last close price of A$0.140/sh: 14.3%
  • Discount to 5 trading day VWAP of A$0.148/sh: 18.9%

Documents & Downloads

De-risked late-stage rare neurodegenerative disease program (NUZ-001) with potential for near-term accelerated approval

  • Convenient to use oral drug with high CNS penetration, with US patent protection to 2041.
  • Rediscovered veterinary product that eliminates toxic protein aggregations, suitable for multiple CNS conditions.
  • Lead program - Amyotrophic Lateral Sclerosis (ALS), most common Motor Neurone Disease – no cure & always fatal.
  • Multi-billion-dollar market with few treatment options.

Elanco (ELAN.NYSE) Strategic Partnership

  • Exclusive global license to Elanco’s veterinary drug for neurodegenerative diseases in humans
  • Access to animal safety and manufacturing data to support accelerated approvals.
  • Commercial-scale drug supply agreement expected to be finalised by the end of CY 2025.

Long-term Safety and Preliminary Efficacy Data in ALS Patients

  • Long-term daily use for more than 2.5 years safe & well tolerated.
  • NUZ-001 slowed the loss of motor function (33%) and respiration (43%), key regulatory endpoints of disease progression
  • Statistically significant survival benefit with outcomes better than other approved ALS treatments

Accelerated Approval Pathway

  • Orphan drug designations in the US and Europe
  • NUZ-001 accepted in competitive HEALEY ALS Platform designed to accelerate most promising ALS therapies:
    • Tests multiple therapies concurrently under a single master protocol across 70+ US sites.
    • Sharing of placebo groups, enables faster enrolment & readout timelines, reduces trial costs & patient burden.
    • Trial design recognised pathway to support accelerated approval process.

FDA Update October 2025

  • NUZ-001 program placed on clinical hold by FDA due to single issue with animal safety margins.
  • Two pharmacokinetic studies were conducted to address the FDA’s concern.
  • Clinical hold complete response submitted, outcome expected by 3 October 2025.

Use of Funds

Use of Funds

1.

Advance pre-clinical programs

2.

HEALEY ALS Platform Trial start-up

3.

GMP manufacturing

4.

Regulatory filings

5.

Working capital

Indicative Timetable

Offer Close Southern Hemisphere 4pm

16 Sep 25

Placement Settlement Date

23 Sep 25

Placement Allotment Date

24 Sep 25

Disclaimer

This site does not constitute an offer, recommendation, or invitation to any person, nor does it purport to provide all of the information an interested party may require in order to investigate the affairs of Neurizon Therapeutics Limited. This site is provided for information only and has not been prepared with the intention that the recipient should rely on it. Liquidity Technology Pty Ltd ("Liquidity") does not make any representation in relation to the contents of this site or give any assurances as to the accuracy or the degree of care or diligence used in preparing this document. The information, data, and advice herein is provided to recipients on the clear understanding that Liquidity nor any of its representatives, directors, officers, employees, agents, or advisers makes any representation or warranty about its accuracy, reliability, completeness, or suitability for any particular purpose and does not accept liability (including, but not limited to, for any expenses, losses, damages, and/or costs (including, but not limited to, indirect or consequential damage)) nor take any responsibility of any kind whatsoever (including, but not limited to, whether in contract, tort, financial or otherwise) for the information, data, or advice contained in or for any omission or for any other information, statement, or representation provided to any recipient (including, but not limited to, as a result of information, data, or advice being inaccurate, unreliable, incomplete, or unsuitable in any way and for any reason whatsoever). Users of this site must conduct their own investigation and analysis regarding any information, statement, or representation contained or provided to any recipient or its associates by Liquidity or any of the Liquidity Personnel. Each recipient waives any right of action, which it has now or in the future against Liquidity or any of the Liquidity Personnel in respect of any errors or omissions on or from this site, however caused. All rights are reserved. If the whole or any part of a provision of this "Notice and Disclaimer" is invalid, illegal, or unenforceable, then such provision will be severed and neither that part or provision or its severance will affect the validity or enforceability of the remaining parts or provisions.

Disclosure of Interest: Liquidity receives commission from dealing in securities and its introducers of business may directly share in this commission. Liquidity and its associates may hold shares in Neurizon Therapeutics Limited.

Neurizon Therapeutics Limited

Placement

Neurizon Therapeutics Limited (ASX:NUZ)

NUZ

Offer Price

A$0.120

per share

Offer Size

A$5,000,000

Cancel

I am a sophisticated 708 investor and agree to the terms and conditions

Neurizon Therapeutics Limited

Follow Neurizon Therapeutics Limited

By submitting your information below you can keep up to date with their relevant news and announcements.

Fields marked with * are required.

Name(Required)

Cancel

Neurizon Therapeutics Limited

Ask Neurizon Therapeutics Limited a question

Ask the company directors a question to understand more about their offering.

Fields marked with * are required.

Name(Required)

Cancel

Neurizon Therapeutics Limited

Submit your details below to get access to the product documents and invest.

Cancel